삼성바이오, 일부 공정 중단 불가피...노조와 대화는 지속

The first-ever labor strike at Samsung Biologics is disrupting the production of critical drugs, posing a significant threat to the company's core competitive edge in delivery reliability and supply chain stability. This situation is particularly critical as it may prompt global pharmaceutical clients to seek more stable alternatives in the US or Europe, potentially hindering long-term expansion plans.